Outputs (15)

3-O-acetyl-11-keto-beta-boswellic acid (β-AKBA) and 11-keto-beta-boswellic acid (β-KBA) increase FoxP3 expression in CD4 (2025)
Journal Article

Boswellic acids (BAs) have multiple beneficial effects against inflammatory and autoimmune diseases. However, their immunomodulatory activities are poorly understood. Herein, we investigated whether individual compounds of BAs including β-BA, β-KBA,... Read More about 3-O-acetyl-11-keto-beta-boswellic acid (β-AKBA) and 11-keto-beta-boswellic acid (β-KBA) increase FoxP3 expression in CD4.

Editorial: Community series in novel biomarkers in tumor immunity and immunotherapy, volume II (2025)
Journal Article

Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors (2025)
Journal Article

Over the past few years, immune checkpoint inhibitors resulted in magnificent and durable successes in treating cancer; however, only a minority of patients respond favorably to the treatment due to a broad-spectrum of tumor-intrinsic and tumor-extri... Read More about Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors.

Cancer-associated fibroblasts in hepatocellular carcinoma: heterogeneity, mechanisms and therapeutic targets. (2025)
Journal Article

Hepatocellular carcinoma (HCC) is one of the common malignant cancers worldwide. Although immunotherapy has improved the treatment outcome in HCC, a significant percentage of patients with advanced HCC still cannot benefit from immunotherapy. Therefo... Read More about Cancer-associated fibroblasts in hepatocellular carcinoma: heterogeneity, mechanisms and therapeutic targets..

Effect of boswellic acids on the expression of PD-1 and TIGIT immune checkpoints on activated human T cells. (2025)
Journal Article

Boswellic acids (BAs) have been documented as anti-inflammatory agents with the potential to regulate immune responses. However, their impacts on the expression level of immune checkpoint (IC) molecules in T cells have never been reported. By using f... Read More about Effect of boswellic acids on the expression of PD-1 and TIGIT immune checkpoints on activated human T cells..

The colorectal cancer microenvironment: Preclinical progress in identifying targets for cancer therapy. (2025)
Journal Article

Colorectal cancer (CRC) is a common cancer with high mortality rates. Despite progress in treatment, it remains an incurable disease for many patients. In CRC, the tumor microenvironment (TME) plays critical roles in tumor growth, progression, patien... Read More about The colorectal cancer microenvironment: Preclinical progress in identifying targets for cancer therapy..

Resistance mechanisms to immune checkpoint inhibitors: updated insights (2025)
Journal Article

The last decade has witnessed unprecedented succusses with the use of immune checkpoint inhibitors in treating cancer. Nevertheless, the proportion of patients who respond favorably to the treatment remained rather modest, partially due to treatment... Read More about Resistance mechanisms to immune checkpoint inhibitors: updated insights.

Effects of 1H-1,2,3-Triazole Derivatives of 3-O-Acetyl-11-Keto-Beta-Boswellic Acid from Boswellia sacra Resin on T-Cell Proliferation and Activation (2024)
Journal Article
Meyiah, A., Avula, S. K., Al-Harrasi, A., & Elkord, E. (in press). Effects of 1H-1,2,3-Triazole Derivatives of 3-O-Acetyl-11-Keto-Beta-Boswellic Acid from Boswellia sacra Resin on T-Cell Proliferation and Activation. Pharmaceuticals, 17(12), 1650. https://doi.org/10.3390/ph17121650

Background: 3-O-acetyl-11-keto-β-boswellic acid (β-AKBA), a triterpene natural product, is one of the main natural products of Boswellia sacra resin (BSR) and has reported biological and immunomodulatory effects. 1H-1,2,3-triazole derivatives of β-AK... Read More about Effects of 1H-1,2,3-Triazole Derivatives of 3-O-Acetyl-11-Keto-Beta-Boswellic Acid from Boswellia sacra Resin on T-Cell Proliferation and Activation.

Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials (2024)
Journal Article
Ren, K., Hamdy, H., Meyiah, A., & Elkord, E. (in press). Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials. Frontiers in Immunology, 15, 1501613. https://doi.org/10.3389/fimmu.2024.1501613

Lymphocyte-activation gene 3 (LAG-3) has emerged as a key immune checkpoint regulating immune responses in the context of cancer. The inhibitory effect of LAG-3-expressing T cells contributes to suppressing anti-tumor immunity and promoting tumor pro... Read More about Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials.

Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach? (2024)
Journal Article
Tripp, R. A., Cui, H., & Elkord, E. (2024). Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?. Vaccines, 12(12), 1306. https://doi.org/10.3390/vaccines12121306

The discovery of immune checkpoints (ICs) has pushed cancer treatment into the next era. As an emerging immune checkpoint, the TIGIT/CD155 axis inhibits the cytotoxicity of T and NK cells through multiple pathways. Immune checkpoint inhibitors (ICIs)... Read More about Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?.